MSCRF Manufacturing Assistance Program
Forecasted
TEDCO’s MSCRF Manufacturing Assistance Program funds Maryland-based research to advance GMP manufacturing of human stem cell therapies and accelerate cell therapy commercialization.
Funder: Maryland Technology Development Corporation (TEDCO)
Due Dates (Anticipated): January 2027 (Mid-January cycle) | June 2027 (Mid-July cycle)
Funding Amounts: Up to $1,000,000 per award (max 24 months); 1:1 non-state match required; total MSCRF FY27 budget is $16.05M (all programs).
Summary: Supports Maryland organizations with GMP manufacturing of human stem cell-based therapies and platforms to accelerate cell therapy commercialization.
Key Information: All research must involve human stem cells or derivatives; work and facilities must be in Maryland.
Description
The MSCRF Manufacturing Assistance Program, administered by TEDCO’s Maryland Stem Cell Research Fund, aims to accelerate the development and GMP-compliant manufacturing of cell therapy products using human stem cells in Maryland. The program provides funding to enable organizations to build or acquire modular manufacturing facilities, clean rooms, or closed systems, and to implement innovative manufacturing solutions that address market needs and foster workforce development in the state’s biotechnology sector. Projects must focus on advancing the production of cell-based therapies and demonstrate clearly defined, achievable milestones.
